NZ715801B2 - Tamper-resistant dosage form containing ethylene-vinyl acetate polymer - Google Patents
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer Download PDFInfo
- Publication number
- NZ715801B2 NZ715801B2 NZ715801A NZ71580114A NZ715801B2 NZ 715801 B2 NZ715801 B2 NZ 715801B2 NZ 715801 A NZ715801 A NZ 715801A NZ 71580114 A NZ71580114 A NZ 71580114A NZ 715801 B2 NZ715801 B2 NZ 715801B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- dosage form
- pharmaceutical dosage
- form according
- eva
- ethylene
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 39
- 229920000642 polymer Polymers 0.000 title claims abstract description 17
- 239000005038 ethylene vinyl acetate Substances 0.000 title claims abstract description 16
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 title claims description 11
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 title claims description 11
- 239000002831 pharmacologic agent Substances 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000000227 grinding Methods 0.000 claims abstract description 5
- 230000000506 psychotropic effect Effects 0.000 claims abstract description 5
- 238000000638 solvent extraction Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 3
- 238000003856 thermoforming Methods 0.000 claims description 3
- 239000008240 homogeneous mixture Substances 0.000 claims description 2
- 239000012943 hotmelt Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 3
- 239000005977 Ethylene Substances 0.000 claims 3
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000155 melt Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/001—Combinations of extrusion moulding with other shaping operations
- B29C48/0011—Combinations of extrusion moulding with other shaping operations combined with compression moulding
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
- B29C48/05—Filamentary, e.g. strands
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C51/00—Shaping by thermoforming, i.e. shaping sheets or sheet like preforms after heating, e.g. shaping sheets in matched moulds or by deep-drawing; Apparatus therefor
- B29C51/002—Shaping by thermoforming, i.e. shaping sheets or sheet like preforms after heating, e.g. shaping sheets in matched moulds or by deep-drawing; Apparatus therefor characterised by the choice of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2023/00—Use of polyalkenes or derivatives thereof as moulding material
- B29K2023/04—Polymers of ethylene
- B29K2023/08—Copolymers of ethylene
- B29K2023/083—EVA, i.e. ethylene vinyl acetate copolymer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0085—Copolymers
Abstract
The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol. st dose-dumping in aqueous ethanol.
Description
It has been surprisingly found that a pharmaceutical dosage form comprising ethylene-vinyl acetate (EV A) polymer and a pharmacologically active ingredient having psychotropic action can be prepared, wherein the pharmaceutical dosage form exhibits tamper resistance, especially in terms of resistance against solvent extraction of the pharmacologically active ingredient, resistance against grinding of the pharmaceutical dosage form, respectively, and resistance against dose-dumping of the pharmacologically active ingredient in aqueous ethanol.
In a first embodiment there is provided a tamper-resistant, oral pharmaceutical dosage form comprising a homogeneous mixture of: (A) a pharmacologically active ingredient having psychotropic action and (B) a prolonged release matrix comprising 55 to 80 wt.-% relative to a total weight of the dosage form of an ethylene-vinyl acetate (EVA) polymer; wherein the EVA polymer provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.
In a second embodiment there is provided a process for the production of the tamper-resistant, oral pharmaceutical dosage form according to the first embodiment, comprising the steps of (i) mixing a pharmacologically active ingredient, 55 to 80 wt.-% relative to a total weight of the dosage form of an ethylene-vinyl acetate (EVA) polymer and optionally one or more further excipients to form a mixture; and (ii) thermoforming the mixture obtained in step (i), wherein said mixture is simultaneously or before or after the application of heat subjected to pressure.
A first aspect of the invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene- vinyl acetate (EV A) polymer, which dosage form provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.
Preferably, the pharmaceutical dosage form according to the invention is thermoformed, more preferably hotmelt extruded. Thermoforming preferably means that in the course of the manufacture of the pharmaceutical dosage form the mixture comprising the EV A polymer and the pharmacologically active ingredient is heated to a temperature above ambient temperature, preferably at least 60 °C or at least 80 °C, and compressed, preferably at pressures of at least 1 bar or at least 2 bar, more preferably at least 10 bar or at least 30 bar. The compression force may be exerted prior to, during or subsequent to the application of heat.
AH26(27800673_1):JIN As used herein, the term "pharmaceutical dosage form" refers to a pharmaceutical entity that is comprised of a pharmacologically active ingredient and which is actually administered to, or taken by, a patient. It may be compressed or molded in its manufacture, and it may be of almost any size, shape, weight, and color.
The pharmaceutical dosage form is preferably solid or semisolid.
Examples of pharmaceutical dosage forms according to the invention include, but are not limited to, tablets, capsules, pills, granules, pellets, sachets and effervescent, powders, and the like. In an embodiment of the present invention, the composition is formulated in a capsule. In accordance with this embodiment, the pharmaceutical dosage form comprises a hard or soft gelatin capsule.
Most pharmaceutical dosage forms are intended to be swallowed whole and accordingly, the pharmaceutical dosage forms according to the invention are designed for oral administration.
In a preferred embodiment, the pharmaceutical dosage form according to the invention is monolithic. In this regard, monolithic preferably means that the pharmaceutical dosage form is formed or composed of material without joints or seams or consists of or constitutes a single unit.
In another preferred embodiment, the pharmaceutical dosage form according to the invention is not monolithic. Preferably, the pharmaceutical dosage form according to the invention is multiparticulate, i.e. comprises a multitude of particles. An advantage of multiparticulate pharmaceutical dosage forms is that the particles may be mixed in different amounts to thereby produce pharmaceutical dosage forms of different strengths.
AH26(27800673_1):JIN
Claims (11)
1. A tamper-resistant, oral pharmaceutical dosage form comprising a homogeneous mixture of: (A) a pharmacologically active ingredient having psychotropic action and (B) a prolonged release matrix comprising 55 to 80 wt.-% relative to a total weight of the dosage form of an ethylene-vinyl acetate (EVA) polymer; wherein the EVA polymer provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.
2. The pharmaceutical dosage form according to claim 1, wherein the pharmaceutical dosage form provides prolonged release of the pharmacologically active ingredient.
3. The pharmaceutical dosage form according to claim 1 or 2, wherein the EVA polymer comprises repetition units derived from ethylene and vinyl acetate and/or vinyl alcohol.
4. The pharmaceutical dosage form according to any one of the preceding claims, wherein the EVA polymer contains at least 50 wt.-% of ethylene repetition units, relative to the total weight of the EVA polymer.
5. The pharmaceutical dosage form according to claim 4, wherein the EVA polymer contains from 50 to 95 wt.-% of ethylene repetition units, relative to the total weight of the EVA polymer.
6. The pharmaceutical dosage form according to any one of the preceding claims, wherein the EVA polymer has a melt flow rate at 190°C and 2.16 kg within the range of from 1 to 160 g/10 min measured according to ASTM D1238.
7. The pharmaceutical dosage form according to any one of the preceding claims, which is monolithic and has a breaking strength of at least 300 N; or which is multiparticulate, wherein at least a fraction of the individual particles have a breaking strength of at least 300 N.
8. The pharmaceutical dosage form according to any one of the preceding claims, which is monolithic and has an extension in any direction of at least 2.0 mm; or which is AH26(27800673_1):JIN multiparticulate, wherein the individual drug-containing particles have an extension in any direction of at least 2.0 mm.
9. The pharmaceutical dosage form according to any one of the preceding claims, wherein the pharmacologically active ingredient is an opioid or a physiologically acceptable salt thereof.
10. The pharmaceutical dosage form according to any one of the preceding claims, which is hot-melt extruded.
11. A process for the production of the tamper-resistant, oral pharmaceutical dosage form according to any one of claims 1 to 10, comprising the steps of (i) mixing a pharmacologically active ingredient, 55 to 80 wt.-% relative to a total weight of the dosage form of an ethylene-vinyl acetate (EVA) polymer and optionally one or more further excipients to form a mixture; and (ii) thermoforming the mixture obtained in step (i), wherein said mixture is simultaneously or before or after the application of heat subjected to pressure. Grünenthal GmbH By the Attorneys for the Applicant SPRUSON & FERGUSON Per: AH26(27800673_1):JIN
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176303 | 2013-07-12 | ||
| EP13176303.9 | 2013-07-12 | ||
| PCT/EP2014/064830 WO2015004245A1 (en) | 2013-07-12 | 2014-07-10 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ715801A NZ715801A (en) | 2021-07-30 |
| NZ715801B2 true NZ715801B2 (en) | 2021-11-02 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5536446B2 (en) | Stabilized composition comprising an alkali labile drug | |
| KR19990063853A (en) | Solid medicaments obtained by extrusion of a heterogeneous malt-containing polymer-active material melt | |
| JP2018517676A5 (en) | ||
| KR20180132141A (en) | Modified release abuse inhibition dosage form | |
| WO2008072532A1 (en) | Pharmaceutical composition having improved storage stability | |
| JP6133445B2 (en) | Oral rapidly disintegrating composition for solid preparation | |
| CN106232144B (en) | Solid dispersion | |
| CA2614085A1 (en) | Pharmaceutical dosage form based on an osmotic active ingredient release system comprising an active ingredient combination of nifedipine and/or nisoldipine and an angiotensin ii antagonist | |
| KR102092423B1 (en) | Rapidly disintegrating tablet | |
| CN102883713A (en) | Alcohol-resistant formulations | |
| JP2022051901A (en) | Extended release, abuse deterrent dosage forms | |
| WO2012053785A3 (en) | Sustained-release pellets containing tacrolimus as an active ingredient | |
| WO2011134962A2 (en) | Orally disintegrating tablet containing acarbose | |
| CN104706640B (en) | A kind of Pharmaceutical composition and its preparation technology containing Irbesartan | |
| JP5442620B2 (en) | Mechanical protective layer for solid dosage forms | |
| CN103372014A (en) | Quickly dissolved-out stable vardenafil hydrochloride oral solid preparation and preparation method thereof | |
| JP6308938B2 (en) | Method for producing granular material | |
| KR101171375B1 (en) | Oral solid dosage form comprising poorly soluble drugs | |
| WO2009084041A3 (en) | Pharmaceutical compositions of dexibuprofen | |
| JP2017502941A5 (en) | ||
| US20190343957A1 (en) | Method Of Manufacturing Fine Particles Suitable For Orally Disintegrating Pharmaceutical Dosage Forms | |
| NZ715801B2 (en) | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer | |
| NZ715801A (en) | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer | |
| CN110325178B (en) | Method for producing preparation with improved content uniformity | |
| CN105311635A (en) | High drug-loading pharmaceutical composition with adjustable release rate and preparation method thereof |